Home › Aggression › NCT05537610
Extensions of Resurgence as Choice
Extensions of Resurgence as Choice: Basic and Clinical Studies
Who can join
Ages 3 to 17 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1. boys and girls from ages 3 to 17; 2. problem behavior that occurs at least 10 times a day, despite previous treatment; 3. problem behavior maintained by social positive reinforcement; 4. stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment; 5. on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free; 6. stable educational plan and placement with no anticipated changes during the child's treatment. Exclusion Criteria: 1. patients who do not meet the inclusion criteria; 2. patients currently receiving 15 or more hours per week of treatment for their problem behavior; 3. DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism); 4. a comorbid health condition or major mental disorder that would interfere with study participation; 5. occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment; 6. patients requiring changes to protective supports for self-injury or drug treatment, but we will invite these patients to participate when protective supports and drug regimen are stable.
About the study
Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the child their way in the natural environment (e.g., caregiver is busy with an infant sibling). This form of treatment relapse is known as resurgence. The goal of the current study is to evaluate whether alternating sessions in which the child can have their way (i.e., "on" sessions) with sessions in which the child can not have their way (i.e., "off" sessions) helps to mitigate resurgence.
What is being tested
- CDT (behavioral)
- Control (behavioral)
Sponsor: Rutgers, The State University of New Jersey · Participants: 30 · Started: Feb 1, 2023
Contact the study team
- Brian Greer, PhD · Phone: 8488008505
- Serena Claiborne · Phone: 8488008504
Official record on ClinicalTrials.gov — NCT05537610
Locations in the U.S.
| New Jersey | Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services, Somerset |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.